BridgeBio Pharma (BBIO) Financial Analysis & Valuation | Quarter Chart
BridgeBio Pharma (BBIO)
BBIOPrice: $72.01
Fair Value: 🔒
🔒score
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs inc... more
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for ... more
Description
Shares
| Market Cap | $14.10B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Neil Kumar |
| IPO Date | 2019-06-27 | CAGR | — |
| Employees | 725 | Website | www.bridgebio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.56% | Total Yield | 0.56% |
BBIO chart loading...
Fundamentals
Technicals
| Enterprise Value | $17.92B | P/E Ratio | -19.25 |
| Forward P/E | 136.57 | PEG Ratio | — |
| P/S Ratio | 26.08 | P/B Ratio | -6.64 |
| P/CF Ratio | -33.88 | P/FCF Ratio | -33.3 |
| EPS | $-3.74 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 355.17% | Gross Margin | 0.94% |
| Operating Margin | -0.98% | Profit Margin | -1.25% |
| ROE | 0.36% | ROA | -0.53% |
| ROCE | -1.03% | Current Ratio | 1.44 |
| Quick Ratio | 1.4 | Cash Ratio | 1.08 |
| Debt/Equity | -1.49 | Interest Coverage | -5 |
| Altman Z Score | -2.41 | Piotroski Score | 2 |